Business Context and Reporting Period
This Form 8-K was filed by LeMaitre Vascular, Inc. on July 13, 2021. The filing serves to announce preliminary unaudited financial results for the quarter ended June 30, 2021, and to disclose the commencement of a securities offering.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing preliminary financial tables for the quarter ended June 30, 2021. However, the text of this Form 8-K does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes and Regulatory Updates
The Company announced the restoration of CE marks for five products under the European Medical Devices Directive, which had previously lapsed due to changes in notified bodies. The updated marks include:
- XenoSure Biologic Patches (Notified Body: TUV SUD; Expiration: May 26, 2024)
- AlboGraft Polyester Vascular Grafts (Notified Body: TUV SUD; Expiration: May 26, 2024)
- Pruitt Carotid Shunts (Notified Body: SGS; Expiration: May 24, 2024)
- Flexcel Carotid Shunts (Notified Body: SGS; Expiration: May 24, 2024)
- AnastoClip Closure Systems (Notified Body: SGS; Expiration: May 24, 2024)
Material Restrictions: The new CE mark for XenoSure excludes neuro and cardiac applications, which were permitted under the prior mark. Additionally, sales under the new mark are restricted to XenoSure made from bovine pericardium sourced from specific suppliers.
Guidance, Outlook, and Other Events
On July 13, 2021, the Company announced the commencement of an offering (details in Exhibit 99.2). No specific financial guidance or management commentary regarding future performance is included in the text of this filing.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific preliminary revenue and earnings figures for the quarter ended June 30, 2021.
- Examine Exhibit 99.2 for details regarding the size, pricing, and terms of the announced securities offering.
- Assess the impact of the restricted indications for XenoSure (loss of neuro/cardiac applications) on European sales projections.
- Verify the supply chain constraints regarding the bovine pericardium sourcing required for the new XenoSure CE mark.